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Islet amyloid polypeptide (IAPP) is a hormone cose-
cretedwith insulinbypancreaticbcells.Uponcontact
with lipid bilayers, it is stabilized into a heterogeneous
ensemble of structural states. These processes are
associated with gains of function, including catalysis
of b sheet-rich amyloid formation, cell membrane
penetration, loss of membrane integrity, and cytotox-
icity. These contribute to the dysfunction of b cells, a
central component in the pathology and treatment of
diabetes. To gain mechanistic insight into these phe-
nomena, a related series of substituted oligoquino-
lines were designed. These inhibitors are unique in
that they have the capacity to affect both solution-
and phospholipid bilayer-catalyzed IAPP self-assem-
bly. Importantly, we show that this activity is associ-
ated with the oligoquinoline’s capacity to irreversibly
adoptanoncovalent fold. This suggests that compact
foldamer scaffolds, such as oligoquinoline, are an
important paradigm for conformational manipulation
of disordered protein state.
INTRODUCTION
The aggregation of proteins is implicated in the pathology of
numerous diseases (Buxbaum and Linke, 2012). For example,
amyloid-b, a-synuclein, and islet amyloid polypeptide (IAPP)
underpin pathology in Alzheimer’s disease (AD), Parkinson’s dis-
ease, and type 2 diabetes, respectively (Hebda and Miranker,
2009). Proteins specific to these disorders undergo a conforma-
tional change from disordered to a cross-b-sheet-rich state.
Transient intermediates of this process are associated with the
toxic gains of function that define disease pathology.
Membrane-bound oligomeric intermediates of the amyloi-
dogenic protein IAPP are hypothesized to contribute to b cell
pathology in diabetes (Haataja et al., 2008) as well as disease
progression in AD (Walsh et al., 2002) and Parkinson’s disease
(Winner et al., 2011). Such oligomers additionally display cell
penetration and mitochondrial dysfunction gains of function
(Magzoub andMiranker, 2012), whichmay account for data sug-
gesting an intracellular location for toxic potential (Gurlo et al.,
2010). Small-molecule approaches have been used to probe
the pathways of IAPP self-assembly. One approach is protein
mimetics, which can serve as a template to match IAPP:IAPP,Chemistry & Biology 21,helix:helix interactions and thereby obstruct protein:protein
interactions (Cummings and Hamilton, 2010). Indeed, several
compounds have been identified that bind to a membrane
stabilized, a-helical subdomain of IAPP (Hebda et al., 2009).
The scaffold, based on oligopyridylamide (OP) (Figure 1A), was
designed to project chemical moieties in a linear fashion, with
spacing that corresponds to the rise per turn of an a helix.
Here, we have taken an alternative approach in which a scaffold
based on oligoquinoline amide (OQ) is used with the intended
goal of its binding and acting as a perturbant of the target pro-
tein structure (Kumar and Miranker, 2013). In essence, we are
comparing the capacity of a foldamer with that of a mimetic to
affect the activity of an intrinsically disordered system.
The goal in foldamer design is to recapitulate properties evident
in proteins (Gellman, 1998). Namely, the small molecule should
cooperatively fold, have a defined and hierarchical structure, and
be formed from a discrete-length polymer capable of variation
without affecting the first two properties. OQs have these proper-
ties and present alternative functional groups with a density that
does not mimic an a helix. We hypothesize that display of compa-
rable moieties on OQ versus OP would create a state requiring a
bound IAPP to change conformation. The size of the change in
IAPP is unimportant except in the requirement that it be sufficient
to affect its capacity to self-assemble. The role of structure forma-
tion byOQand themolecularmechanism of perturbation of IAPPs
gains of function are directly evaluated in this work.RESULTS
A series of OQs (Figure 1) were synthesized and used to make
direct comparisons with OP scaffolds previously reported by
us for the inhibition of membrane-catalyzed IAPP self-assembly
(Hebda et al., 2009). The pentameric OQ, OQ5, inhibits large
unilamellar vesicle (LUV)-catalyzed conversion of IAPP to a b
sheet-rich state. Upon exposure to 630 mM LUVs formed from
a 1:1 mixture of anionic (dioleoylphosphatidylglycerol [DOPG])
and zwitterionic (dioleoylphosphatidylcholine [DOPC]) lipids,
30 mM IAPP undergoes a transition from a predominantly random
coil conformation to one that includes strong spectroscopic con-
tributions from a-helical structures (Figure 2A). After 1 hr, the
protein converts to b sheet-rich species evident by a single Cot-
ton effect minimum near 218 nm. The presence of equimolar
OQ5 prohibits this conversion, with a-helical states still dominant
after 2 hr (Figure 2A; Figure S6 available online). Imaging studies
further show filamentous aggregate end-products, but only
for reactions conducted in the absence of OQ5 (Figures 2B
and 2C). The presence of OQ5 plainly results in the delayed775–781, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 775
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Figure 1. Chemical Structures Used in This Study
(A and B) Line drawings of small molecules and primary sequences of human and rat variants of IAPP: (A) OQs and OPs and (B) EGCG and acid fuchsin. IAPP
contains the indicated disulfide bond and is posttranslationally amidated at its C terminus. A subdomain spanning residues 20 to 29, IAPP20–29, is shown in green,
and basic residues are shown in blue.
(C) OQ5 adapted from the crystal structure of a larger polymer (Gillies et al., 2006). The magenta spheres are substitutable R groups, which for OQ5 are COOH.
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Folded Small Molecule Manipulation of IAPPconversion of IAPP to a filamentous b sheet-rich state without
diminishing the sampling of a-helical conformations.
Lipid-catalyzed IAPP fibrillation is more inhibited by OQ5 than
by OP5. Reactions were initiated by dilution of a 1 mM stock
solution of IAPP into a standard buffer (see Experimental Proce-
dures). Changes in the fluorescence intensity of an exogenously
added fluorophore, thioflavin T (ThT), allowed real-time moni-
toring of the fibrillation (Wolfe et al., 2010). Under these condi-
tions, conversion of 10 mM IAPP to an aggregated state occurs
with a reaction time midpoint (t50) of 22 ± 2 hr. In contrast, fibril-
lation is strongly accelerated by the presence LUVs (Figure 2D).
The t50 for 10 mM IAPP catalyzed by LUVs is 1.0 ± 0.1 hr, consis-
tent with our previously published reports (Hebda et al., 2009).
Addition of 100 mM OP5 to an otherwise matched reaction
results in inhibition of aggregation t50 by a factor of 3 (Fig-
ure 2D). Addition instead of 100 mMOQ5 resulted in no detection
of fibers. Using light scatter instead of ThT gave comparable
results (Figures S1 and S3). OQ5 is plainly a more potent inhibitor
of lipid catalyzed fiber formation than OP5.
Reaction inhibition is sensitive to the repeat number of the
mimetic subunit. For both the OP and OQ compound series, in-
hibition increases with increasing length (n = 1–5) (Figure 2E). The
effect of OP compounds saturates at n = 4 or 5 and displays
inhibition of 3- to 4-fold at an OP/IAPP ratio of 10:1. In contrast,
OQ compounds do not behave methodically for n < 5. At n = 5,
inhibition is abruptly complete (i.e., >20 hr). Lowering the small776 Chemistry & Biology 21, 775–781, June 19, 2014 ª2014 Elseviermolecule/IAPP ratio to 1:1 exaggerates this observation, with
only OQ5 showing any apparent inhibition (Figure 2F).
OQs affect IAPP through a mechanism that is distinct from oli-
gopyridyls. IAPP self-assembly was observed under buffer-only
conditions (no LUVs). At 40 mM IAPP, the t50 for IAPP fibrillation
is 1.9 ± 0.1 hr (Figure 3A). The presence of equimolar OP5 instead
results in a t50 of 1.1 ± 0.1 hr (i.e., OP5 is a mild agonist under
bilayer-free conditions). In contrast, OQ5 is a strong inhibitor. At
a ratio of only 10:1 (IAPP/OQ5), 3- to 4-fold inhibition is apparent
(Figure 3A). At 1:1, no conversion is apparent, even after 22 hr.
Observations using light scatter, circular dichroism (CD) and
transmission electron microscopy (TEM) imaging give compara-
ble results (FigureS1). Inpart, theseobservations canbeaconse-
quence of OQ5 effects on fiber elongation. In the presence of
LUVs, a 10 mM reaction of IAPP is accelerated 5- to 6-fold by
the addition of 0.1 mM IAPP as preformed fibers. One equivalent
of OQ5 is sufficient to negate this acceleration, while 10 equiva-
lents eliminates fiber formation (Figure S4A). Similarly, in the
absence of a bilayer catalyst, 0.1 equivalent of OQ5 is sufficient
to negate seeded acceleration (Figure S4B). This stands in
marked contrast to OP5, in which 1 equivalent of small molecule
is shown to have little effect on seeded reactions (Hebda et al.,
2009). Thus, under matched conditions, OP5 is either neutral or
acts as an agonist, while OQ5 acts as a potent antagonist.
Numerous small molecules have previously been reported
as inhibitors of IAPP fiber formation. Here, we assessLtd All rights reserved
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Figure 2. Effect of Alternative Ligands on Lipid-Catalyzed IAPP Fibrillation
(A) CD spectra of 30 mM IAPP in the presence and absence of 630 mM (monomer units) unilamellar liposomes and/or 30 mM OQ5.
(B and C) Negative-stain TEM images of 10 mM IAPP incubated in reaction buffer for 2 hr in the presence (C) or absence (B) of 10 mM OQ5.
(D) Representative kinetic profiles of 10 mM IAPP fibrillation initiated in the absence and presence of 100 mM ligands and detected by changes in the intensity of
an indicator fluorophore (see Experimental Procedures). (Inset) A sigmoidal fit is used to determine the time required to reach 50% conversion, t50.
(E and F) Comparison of the relative (rel.) t50 values of 10 mM IAPP fibrillation by 100 mM (E) and 10 mM (F) of OQs (blue) and OPs (red). The reported t50 values were
calculated from sigmoidal fit using Origin 5.0 from three independent experiments, with margin of error reported as SD.
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Folded Small Molecule Manipulation of IAPPepigallocatechin-3-gallate (EGCG) and acid fuchsin. EGCG in-
hibits amyloid formation of many proteins, including a-synuclein
and Ab-peptide and is currently under phase 2 clinical trials for
AD (Bieschke et al., 2010). These molecules show significant
(3- to 4-fold) inhibitory capacity in the absence of bilayer at an
equimolar protein/compound ratio (Figure 3B). For both com-
pounds, however, no inhibition of IAPP assembly is apparent
for lipid-catalyzed fibrillation. OQ5 is a particularly unusual inhib-
itor of IAPP that functions effectively under both solution-phase
and lipid bilayer-catalyzed conditions.
OQ5 binds to the a-helical subdomain of IAPP. OQ5 was
titrated into a solution of 15N rat IAPP (rIAPP) and assessed for
structural changes using nuclear magnetic resonance (NMR)
(Figure 4A). Because of the amyloidogenic nature of human
IAPP (hIAPP) under the NMR conditions, a sequence variant of
IAPP from rodents (rIAPP) was used. We have previously shownChemistry & Biology 21,that disruption of b sheet formation strongly diminishes cytotoxic
potential using rIAPP and its helical subdomain variant (H18R).
This result has been recently confirmed (Cao et al., 2013). Impor-
tantly, elevation of peptide concentration to 200 and 50 mM,
respectively, results not only in the restoration of colorimetrically
assessed toxicity but also in a concentration-dependent
mitochondrial localization phenotype (Magzoub and Miranker,
2012). By NMR, the residues affected byOQ5, 3 to 20 (Figure 4B),
have been previously identified by us and others to be part of the
region of IAPP that adopts a helical structure upon interaction
with bilayer surfaces (Apostolidou et al., 2008; Williamson
et al., 2009). Thus, OQ5 likely interacts with IAPP in a manner
that stabilizes and/or perturbs one or more forms of its a-helical
subdomains. The NMR study supports our hypothesis that OQ5
alters IAPP structure. Titration was limited to a stoichiometric
ratio of 4:1 (OQ5/rIAPP) as a result of limited solubility of OQ775–781, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 777
A B Figure 3. Comparison of the Effect of Alter-
native Ligands on IAPP Fibrillation
Reaction profiles shown at stoichiometric ratios of
1:1 (filled) and 1:10 (open) (small molecule/IAPP).
(A) Kinetic assays were performed at 40 mM IAPP
in the absence of LUVs. Representative profiles
are shown for OQ5 and OP5 only.
(B) Comparison of ligand activity toward 40 and
10 mM of IAPP fibrillation under lipid-free and lipid-
catalyzed conditions, respectively. All t50 values
are expressed as t50 in the presence of compound
divided by the t50 of a compound-free control
reaction.
All error bars represent standard deviations from a
minimum of three repeated measurements.
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Folded Small Molecule Manipulation of IAPP(OQ5) at the higher IAPP concentrations required for NMR. The
absence of titration sensitivity across central regions of the rIAPP
sequence is not the result of mutation. A key subpeptide outside
the helical subdomain of IAPP, hIAPP20–29, was independently
examined. This subregion is the hypothesized site of amyloid
nucleation, likely catalyzed by high local concentrations created
by helical assembly of IAPP’s N-terminal domain (Ruschak and
Miranker, 2009). The kinetic profile of 200 mM hIAPP20–29 shows
nucleation-dependent kinetics with a t50 of 6.2 ± 0.1 hr (Fig-
ure 4C), consistent with the results of previous studies assessing
the independent behavior of this peptide. Inclusion of stoichio-
metric OQ5 in an otherwise matched reaction results in no
change in the fiber formation profile. OQ5 inhibition of full-length
hIAPP at 1:1 stoichiometry (Figure 3A) is therefore unlikely to be
the result of interactions with the 20–29 subdomain.
DISCUSSION
The development of synthetic foldamers is inspired by the ca-
pacity of proteins to fold to a conformationally restricted state
and, from that state, achieve strongly specific molecular interac-
tions (Guichard and Huc, 2011). OQ, a recent addition to the fol-
damerome (Gellman, 1998), has recently been identified by us
to have the capacity to affect IAPP amyloid formation. Themech-
anism and effects of this interaction remained elusive. Here,
we have made a series of foldamers and made comparisons
both with a series of comparably derivitized protein mimetics
and with literature compounds identified through screening.
Our findings show that OQs (1) specifically and uniquely inhibit
lipid-catalyzed as well as solution-phase amyloid nucleation
and elongation processes, (2) perform this inhibition by interact-
ing with a specific structural subunit of IAPP, and (3), acquire
these capacities in a manner that is strongly nonlinear in terms
of its dependence on OQ subunit length. Our observations sug-
gest that folded and not unfolded OQs represent the paradigm
for targeting weakly ordered states of IAPP.
A plethora of small molecules have previously been identified
that inhibit IAPP fibrillation, such as, polyphenols (Meng et al.,
2010b), resveratrol (Mishra et al., 2009), phenolsulfonphthalein
(Levy et al., 2008), EGCG derivatives (Meng et al., 2010b), acid
fuchsin (Meng et al., 2010a), and IAPP derivatives (Yan et al.,
2006). Typically, such molecules are identified using assays
thatmeasure only solution-phase fibrillation. The collective result
appears to be a set of molecules dominated by planar aromatic778 Chemistry & Biology 21, 775–781, June 19, 2014 ª2014 Elsevierscaffolds. In the case of N-methyl derivatives of IAPP (Yan et al.,
2006), the likely mechanism is not intercalation, but rather a crys-
tal poisoning-like interaction that halts efficient elongation. In
both sets of mechanisms, b sheet structure formation represents
the macromolecular target.
The capacity of OQ5 to inhibit lipid-catalyzed assembly re-
flects the contribution of a-helical intermediate states to IAPP
gains of function. Far-UV CD and NMR suggest that OQ5 is inter-
acting directly with the membrane-bound helical substates
of IAPP (Figure 4) (Williamson et al., 2009). In addition, we per-
formed assays looking for inhibition of IAPP20–29 fibrillar assem-
bly. This subunit assembles by direct nucleation from a random
coil to a b sheet state (Ruschak and Miranker, 2007). No inhibi-
tion byOQ5was observed (Figure 4C). Additionally, fluorescence
correlation spectroscopy (FCS) data suggest that IAPP interac-
tions with membranes are weakened by interactions with OQ5
(Figure S5). In solution, it is plausible that the inhibitory mecha-
nism involves an alternate structure such as b sheet. Random
coil still dominates for IAPP:OQ5 in free solution, potentially
masking a low population of structured states (Figure S6D).
However, we have shown that a subset of IAPP residues weakly
samples a-helical states even in the absence of membrane.
Addition of a membrane model simply stabilizes this subpopula-
tion (Williamson et al., 2009). The fact that OQ5 operates substoi-
chiometrically for IAPP in free solution might reasonably be
attributed to interactions with this small population. In total,
these observations strongly support our assertion that OQ5 inter-
acts with and affects amyloid assembly through interactions with
the a-helical state of IAPP.
The adoption of a folded compact state underpins OQ’s ca-
pacity to affect IAPP. OQs undergo a dramatic change in their ef-
ficacy upon reaching a subunit length of five (Figures 2E and 2F).
This change is not accounted for by charge pairing, as hIAPP
contains only two or three positive charges. Five units is the min-
imum required for OQ to complete one unit of its noncovalent
fold (Figure 1). In addition, previous studies have shown that pen-
tameric and not shorter polymers of OQ collapse into left- and
right-handed states that do not interconvert in aqueous solution
(Qi et al., 2012). We therefore suggest that only at five units is OQ
able to adopt the folded structure that is essential for its function.
In conclusion, an OQ-based scaffold has been identified that
affects amyloid self-assembly by IAPP through a mechanism
that differs from earlier reported compounds. To our knowl-
edge, carboxylate-substituted OQ5 is the most effective IAPPLtd All rights reserved
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Figure 4. Structural Analysis of IAPP:OQ5 Interactions
(A) Overlay of the changes in chemical shifts in 1H-15N heteronuclear single quantum coherenceNMR spectra of 120 mM15N-labeled rIAPP titratedwithOQ5 at the
indicated stoichiometries.
(B) Sequence dependence of combined 15N/1H chemical shifts at a stoichiometric ratio of 4:1 (OQ5/IAPP) (Grzesiek et al., 1996).
(C) Effect of equimolar OQ5 on the kinetic profile of 200 mM hIAPP20–29 fibrillation.
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lipid-catalyzed solution conditions. This represents a useful
paradigm in which a folded small molecule serves to conforma-
tionally capture an off-pathway state of an intrinsically disor-
dered peptide toxin. Indeed, this goal is central to many other
systems, including Ab, a-synuclein, and others that sample a
diverse set of conformational states. OQs are a vital and distinct
class of compound to add to these important efforts.
SIGNIFICANCE
Heterogeneous disorder-to-order transitions are central to
the development of cytotoxicity in many diseases, including
AD, Parkinson’s disease, and type 2 diabetes. The intrinsi-
cally disordered protein precursors in these systems lack
stable secondary structure and exist as an ensemble of
rapidly fluctuating intermediates states. Nevertheless, they
canmake structure-specific interactions. IAPP, a 37-residue
hormonal peptide cosecreted by pancreatic b cells, samples
a series of intermediate states contributing to gain of toxic
function in diabetes. Few tools, however, can illuminate
the subset of structures that give rise to any particular pro-
tein activity. A foldamer-based scaffold, here based on OQ,
offers an opportunity that in effect inverts the problem of
molecular recognition. A designed, noncovalent interaction
based on a folded and compact small molecule becomes
the object about which a flexible and dynamic protein can
bind. This pairing of synthetic chemistry with molecular
biophysics offers a powerful paradigm for addressing
dynamic protein targets.
EXPERIMENTAL PROCEDURES
Chemical Compounds
ThT was purchased from Acros Organics. Lipids (DOPG and DOPC) were pur-
chased fromAvanti Polar Lipids.Ninety-six-well plates (coated, nonbinding sur-
face, black, flat bottom) were bought fromGreiner Bio-One. All chemicals were
purchased from commercial suppliers and used without further purification.
Silica plates (w/UV254, aluminum backed, 200 mm) and silica gel (standardChemistry & Biology 21,grade, particle size 40–63 mm, 230 3 400 mesh) for flash column chromatog-
raphy were purchased from Sorbent Technologies. Dry solvents were pur-
chased from Sigma Aldrich or VWR. Triethylamine (dry), 2-chloro-1-methylpyr-
idinium iodide, tert-butyl bromoacetate, 2-nitroaniline, dimethylacetylene
dicarboxylate, and polyphosphoric acid were purchased from Sigma Aldrich.
Materials
15N wild-type rIAPP was prepared by recombinant E. coli purification as
described previously (Williamson and Miranker, 2007). Human IAPP was syn-
thesized using t-Boc methods and purified at the W.M. Keck facility. Fluores-
cently labeled protein was prepared using amine coupling, by reacting rIAPP
with TAMRA-SE (5-carboxytetramethyl rhodamine succinimidyl ester; Life
Technologies) for 2 hr at room temperature in 10 mM potassium phosphate
(pH 7.2). Labeled rIAPP was separated from free dye using a HiTrap Sephadex
G-25 column (GE Healthcare).
Synthesis of OQs
The synthesis of OQs was carried out using linear solution-phase iterative
amide coupling with a slight modification in the previously reported procedure
(Jiang et al., 2003). The starting material, methyl 8-nitro-(1H)-4-quinolinone-2-
carboxylate, was synthesized according to the known procedure and then
functionalized by introducing O-tert butyl ester as side chain. Chain elongation
was achieved using successive amide coupling (in the presence of 2-chloro-1-
methylpyridinium iodide) and reduction of nitro group. The acid labile tert-butyl
ester derivatized OQs were then treated with trifluoroacetic acid (TFA) cocktail
(TFA/triethylsilane/dichloromethane, 10:2.5:87.5 v/v) to afford the carbox-
ylate-substituted OQs in modest yield. The OQs were purified using high-per-
formance liquid chromatography and characterized for identity using NMR,
mass spectrometry electrospray ionization, and elemental analysis (see syn-
thesis and characterization of OQs for details).
Preparation of IAPP
IAPP (2 mg) was solubilized in 7 M guanidinium chloride solution. The solu-
tion was filtered (0.2 mm) and transferred to a C-18 spin column, washed twice
with water (400 ml each) and 10% acetonitrile in water, 0.1% formic acid (v/v),
and then eluted with 200 ml of 50% acetonitrile in water, 0.1% formic acid (v/v).
The concentration of IAPP (oxidized form) was calculated using absorbance
measurements at 280 nm (ε = 1,400 M1cm1). The IAPP solution was divided
into several aliquots (50–100 mL, 1–2 mM), lypholized, and stored at 80C.
Fresh stock solutions of IAPP were prepared in water for each experiment.
Preparation of Unilameller Vesicles
LUVs were composed from a mixture of DOPG and DOPC in a 1:1 molar ratio.
The solution of DOPG andDOPC in chloroform (25mg/ml each) was firstmixed775–781, June 19, 2014 ª2014 Elsevier Ltd All rights reserved 779
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The mixture was hydrated in 100 mM KCl and 50 mM sodium phosphate at
pH 7.4 for 20 min. A 20 mg/ml solution of lipid in buffer was passed 21 times
through an extrusion film (size 100 nm). The phospholipid content of the final
material was also confirmed by measurement of total phosphorous (Chen
et al., 1956).
Kinetic Assay
Unless otherwise stated, kinetic reactions were conducted in buffer con-
tains liposome (500 mg/ml) and 20 mM ThT in a Microfluor 1 black 96-well
plate (Thermo Electron). This was followed by addition of the small mole-
cule dissolved in DMSO (final DMSO concentration 0.1%, v/v). Fiber forma-
tion was initiated by addition of IAPP stock solution (final concentration
10 mM). Final volume in each well was 200 mL. The kinetics of IAPP fibrilla-
tion were monitored using ThT fluorescence (Ex 450 nm and Em 485 nm)
using a FluoDia T70 fluorescence plate reader (Photon Technology Interna-
tional). The data were blank-subtracted and renormalized to the maximum
intensity of reactions containing only IAPP. All ThT assays were performed
in triplicate.
Reaction profiles were fit using the built-in sigmoidal fit in Origin 5.0
separately for each run. This was used to extract separate t50 (time required
to reach 50% fluorescence) from which averages and SDs were calculated.
All presented fits were normalized for clarity. Kinetic assays under lipid-free
conditions were repeated in the same way as mentioned above, except that
no lipid was present.
CD Spectroscopy
CDmeasurements were made at room temperature on an Aviv 215 spectrom-
eter using 1mmpath length cuvettes. The stock solution of IAPP (1–2mM) was
diluted to 30 mM IAPP in 100 mMKCl and 50 mM sodium phosphate at pH 7.4.
Spectra were collected at 0.5 or 1 nm intervals from 195 to 260 nm with 10 s
averaging time. The lipid-catalyzed CD spectra were recorded using a similar
method as described above except in the presence of liposome (500 mg/ml,
DOPG/DOPC 1:1, 100 nm).
Electron Microscopy
IAPP (40 mM) was incubated in buffer (100mMKCl, 50 mM sodium phosphate,
pH 7.4) in both the absence and presence of OQ5. Aliquots of these samples
were then applied on glow-discharged (25 mA and 30 s) carbon-coated
300-mesh copper grids for 1 min and then dried. Grids were then negatively
stained for 1 min with uranyl acetate (2%, w/v) and dried. Micrographs of grids
were examined on a Phillips Tecnai 12 transmission electron microscope
at 120 kV accelerating voltages. All conclusions drawn from images in this
work include at least one repeat in which the sample identity was withheld
from the investigator preparing and analyzing images.
FCS
FCS measurements were collected on a home-built instrument as previ-
ously described (Nath et al., 2010). Autocorrelation traces were analyzed using
custom MATLAB (The MathWorks) scripts.
FCS samples contained 10 nM TAMRA-labeled rIAPP in 20 mM Tris
(pH 7.4), 100 mM NaCl, and varying concentrations of compounds of interest
added from aqueous (OQ5) or DMSO (all other compounds, final DMSO
concentration 0.5%, v/v) stocks. For IAPP-lipid binding experiments (Fig-
ure S5), 5 mM of liposome (DOPG/DOPC 1:1, 100 nm) was added to samples.
Between ten and 30 measurements of 10 s each were averaged for each
FCS observation.
All data were fit to a single-component, 3D diffusion model to extract an
apparent diffusion time parameter, tD, that quantified changes in the hydrody-
namic properties of IAPP:
GðtÞ= 1
N

1+
t
tD
1
1+
t
s2tD
1 =2
: (Equation 1)
Here, G(t) represents the normalized autocorrelation at lag time t, N repre-
sents themean number ofmolecules in the observation volume, s is a structure
factor that describes the prolate shape of the observation volume, and tD is the
diffusion time.780 Chemistry & Biology 21, 775–781, June 19, 2014 ª2014 ElsevierNMR Titration
All data were collected using a Varian 600 MHz wide-bore spectrometer with
a triple-resonance HCN probe. All experiments were performed under similar
solution conditions (10% D2O in 150 mM KCl, 50 mM sodium phosphate,
pH 6.5). Titration of OQ5 was performed into a 120 mM
15N-rIAPP sample.
The dilution of rIAPP by the titration of OQ5 was <6%. Reported D ppm values
were obtained by scaling the contributions for the proton and nitrogen dimen-
sions (Grzesiek et al., 1996).
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